DRG Market Assessment reports

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate Epidemiology’s coverage of irritable bowel syndrome (IBS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IBS for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key irritable bowel syndrome patient populations, covering 171…

TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the total and diagnosed prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key celiac disease patient populations, covering 171 countries and more…

Multiple well-established therapies are available to treat Crohn’s disease (CD). The mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen / Merck’s Remicade, AbbVie / Eisai’s…